Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 2/20 | 0.39 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | JAK2 | O60674 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | HPGDS | O60760 | 5/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | NLRP3 | Q96P20 | 3/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25332801 | 1.00 | MTNR1A (0.39) | MTNR1AMTNR1BGAAJAK2ALDH1A1 | |
| SCHEMBL25952839 | 0.82 | MTNR1A (0.40) | MTNR1AMTNR1BGAAHPGDSHTT | |
| SCHEMBL20464452 | 0.82 | MTNR1A (0.40) | MTNR1AMTNR1BGAAHPGDSHTT | |
| SCHEMBL29494819 | 0.81 | GAA (0.58) | GAAHTTKDM4EKMT2A | |
| SCHEMBL228314 | 0.79 | HDAC4 (0.38) | MTNR1AMTNR1BGAAJAK2ALDH1A1 | |
| SCHEMBL2302250 | 0.79 | MAOB (0.48) | MTNR1AMTNR1BGAAJAK2ALDH1A1 | |
| SCHEMBL2302254 | 0.79 | GAA (0.50) | MTNR1AMTNR1BGAAJAK2ALDH1A1 | |
| SCHEMBL18343146 | 0.78 | MTNR1A (0.40) | MTNR1AMTNR1BGAAJAK2ALDH1A1 | |
| SCHEMBL20313800 | 0.75 | MTNR1A (0.36) | MTNR1AMTNR1BGAAJAK2ALDH1A1 | |
| SCHEMBL14809937 | 0.74 | POLB (0.36) | GAAHPGDSHTTKDM4EKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230357162-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | TENVIE THERAPEUTICS, INC. | 2023-11-09 | — | — | US | disclosed |
| US-20230357162-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | TENVIE THERAPEUTICS, INC. | 2023-11-09 | — | — | US | disclosed |
| US-20230348437-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | TENVIE THERAPEUTICS, INC. | 2023-11-02 | — | — | US | disclosed |
| WO-2023133271-A1 | BICYCLIC PHTHALAZIN-1(2H)-ONE DERIVATIVES AND RELATED USES | NodThera Limited (GB) | 2023-07-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230357162-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | NLRP3, NLRP1, NOD1 | MTNR1A 3778/4885MTNR1B 3871/4885GAA 4485/4885 |
| US-20230348437-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | NLRP3, NLRP1, NOD1 | MTNR1A 3778/4885MTNR1B 3871/4885GAA 4485/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.